Cập nhật tin tức mới nhất về tiền kỹ thuật số, giá cả và hơn thế nữa
BusinessGlobeNewswire
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions …